de Juan, A.
Redondo, A.
Rubio, M. J.
García, Y.
Cueva, J.
Gaba, L.
Yubero, A.
Alarcón, J.
Maximiano, C.
Oaknin, A.
Article History
Received: 10 December 2019
Accepted: 10 December 2019
First Online: 24 January 2020
Compliance with ethical standards
:
: AdJ reports personal fees and other from Roche, AstraZeneca, Pharma Mar, Clovis Oncology, Tesaro, Eisai Ltd, Pierre-Fabre and Pfizer, outside the submitted work. AR reports grants and personal fees from Pharmamar and Roche, personal fees from Lilly, Novartis, Amgen, Astra Zeneca, Tesaro and grants from Eisai, outside the submitted work. MJR has nothing to disclose. YG has nothing to disclose. JC reports Grants from Roche, outside the submitted work. LG has nothing to disclose. AY has nothing to disclose. JA reports personal fees and non-financial support from Hoffmann-La Roche and Clovis Oncology, non-financial Support from Merck Sharp and Dohme (MSD) and Pharma Mar, outside the submitted work. CM has nothing to disclose. AO reports personal fees and other from Roche, AstraZeneca, Pharma Mar, Clovis Oncology; personal fees from Tesaro, Immunogen, Genmab, Amgem, AbbVie, Merck; grants from Abbie Deutchland, Ability Pharmaceuticals, Advaxis Inc, Aeterna Zentaris, Amgen SA, Aprea Therapeutics AB, Clovis Oncology Inc., Eisai Ltd, F. Hoffmann-La Roche Ltd., Regeneron Pharmaceuticals, Immunogen Inc., Merck Sharp & Dohme de España SA, Millennium Pharmaceutials Inc., PharmaMar, Tesaro Inc., Bristol Meyers Squibb, BMS, outside the submitted work.
: The current study has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.
: For this type of retrospective study, formal consent is not required.